Comparing transarterial chemoembolization alone to combined transarterial chemoembolization and radiofrequency ablation in primary hepatocellular carcinoma treatment

Table 1 Demographic and clinical characteristics of patients in the transarterial chemoembolization and transarterial chemoembolization + radiofrequency ablation treatment groups

Parameter	TACE group (n = 56)	TACE + RFA group (n = 50)
Male	35	31
Female	21	19
Child-Pugh class A	42	39
Child-Pugh class B	14	11
BCLC stage B	31	25
BCLC stage C	18	18
BCLC stage D	7	7
AFP > 200 μg/L	23	19
Mean tumor diameter (cm)	6.9 ± 1.08	7.01 ± 1.18
Median age (years)	56	53
Age range (years)	39-71	35-73

TACE: Transarterial chemoembolization; RFA: Radiofrequency ablation; BCLC: Barcelona Clinic Liver Cancer; AFP: Alpha-fetoprotein.